SCHEMBL7490324

SCHEMBL7490324

COc1c(Cl)cccc1NC(=O)Nc1ccc(C#N)cc1NS(=O)(=O)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 2/20 0.47
ACLY P53396 4/20 0.46
KMT2A Q03164 6/20 0.45
MEN1 O00255 5/20 0.45
LMNA P02545 3/20 0.45
MAPT P10636 3/20 0.45
MAPK1 P28482 2/20 0.45
NPSR1 Q6W5P4 2/20 0.45
AVPR2 P30518 1/20 0.45
GPR27 Q9NS67 1/20 0.45
ALOX12 P18054 1/20 0.45
HTT P42858 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
KDM4E B2RXH2 3/20 0.44
ALDH1A1 P00352 1/20 0.44
HSD17B10 Q99714 1/20 0.44
CXCR1 P25024 2/20 0.43
CXCR2 P25025 2/20 0.43
STAT3 P40763 1/20 0.43
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7490402 0.88 GPR27 (0.51) CCR2KMT2AMEN1LMNAMAPT
SCHEMBL7491182 0.87 GPR27 (0.51) CCR2KMT2AMEN1LMNAMAPT
SCHEMBL7553684 0.85 MEN1 (0.57) CCR2ACLYKMT2AMEN1LMNA
SCHEMBL7487824 0.81 TBXA2R (0.50) CCR2ACLYMAPK1NPSR1HTT
SCHEMBL7940030 0.79 HDAC1 (0.50) CCR2ACLYAVPR2GPR27CXCR1
SCHEMBL7496445 0.79 ACLY (0.52) CCR2ACLYKMT2AMEN1LMNA
SCHEMBL3709166 0.79 CXCR2 (0.63) CCR2KMT2AMEN1LMNAAVPR2
SCHEMBL8684465 0.79 CXCR1 (0.43) CCR2ACLYKMT2AMEN1LMNA
SCHEMBL7557174 0.79 PTGES2 (0.45) CCR2ACLYKMT2AMEN1LMNA
SCHEMBL7493701 0.79 STAT3 (0.51) CCR2ACLYLMNAAVPR2GPR27

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0896531-A4 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2002-10-30 EP disclosed
US-20020128321-A1 IL-8 receptor antagonists SMITHKLINE BEECHAM CORPORATION 2002-09-12 US disclosed
US-6262113-B1 HYDROXY- OR MERCAPTO-PHENYLUREAS SMITHKLINE BEECHAM CORPORATION 2001-07-17 US disclosed
US-6211373-B1 Phenyl urea antagonists of the IL-8 receptor SMITHKLINE BEECHAM CORPORATION 2001-04-03 US disclosed
EP-0896531-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1999-02-17 EP disclosed
WO-1997029743-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1997-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128321-A1 IL-8 receptor antagonists CXCL8, CCR8, IL1RN CCR2 5/4885ACLY 4691/4885KMT2A 3978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.